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Background: Dietary nitrate supplementation has been shown to decrease the oxygen cost of exercise and
prolong exercise tolerance, as measured by sub-maximal exercise endurance distance and time at 85% V̇O2max, in
both elite athletes and normal healthy subjects. Patients with chronic obstructive pulmonary disease (COPD) have
reduced quality of life and ability to perform activities of daily living attributable to diminished exercise tolerance,
and dietary nitrate may be able to ameliorate this.
Methods: We performed a double-blind, computer-randomized placebo control crossover trial at a tertiary Australian
hospital to investigate whether dietary nitrate supplementation as beetroot juice (BR) would augment submaximal
exercise endurance in individuals with spirometrically confirmed stable moderate COPD. Volunteers underwent an
incremental shuttle walk test to determine V̇O2max followed by a test dose of BR to establish safety in the study
population. Participants performed an endurance shuttle walk test (ESWT) at 85% V̇O2max after randomization to either
a 3 day wash-in of BR (4.8 mmol twice a day) or placebo (nitrate deplete BR), with a final dose on the morning of
testing. They then crossed over after 4 day washout. Repeated measures two sided paired t-tests were employed.
Results: 35 participants were recruited with 19 completing the trial. In the initial safety phase, we measured systolic
blood pressure over four hours post first dose of BR, and found a mean 10 mmHg decrement maximal at 1 hour. One
individual developed symptomatic postural hypotension and was excluded. The primary outcomes of ESWT distance
and time to fatigue improved by 11% and 6% respectively; however these differences did not achieve statistical
significance (p = 0.494 and 0.693 respectively).
Conclusions: Our study does not support a role for routine dietary nitrate supplementation for enhancement of
exercise endurance in COPD.
Trial registration: Australia and New Zealand Clinical Trial Register: ACTRN12611001088932
Keywords: COPD, Dietary nitrate, Exercise performance, Incremental shuttle walk test, Randomized control trialBackground
Chronic Obstructive Pulmonary Disease (COPD) is a
leading cause of morbidity worldwide, with a substantial
and increasing economic and social burden: it is esti-
mated that 64 million people are affected worldwide
[1,2]. Exercise intolerance and fatigue are major negative* Correspondence: paul.leong@monashhealth.org
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unless otherwise stated.contributors to quality of life in individuals with COPD,
for whom the activities of daily living may embody a sig-
nificant exercise challenge [3].
Pharmacological inorganic nitrate (NO3
−) supplementa-
tion reduces the O2 cost of and enhances high-intensity
exercise tolerance in humans [4]. In a placebo-controlled
study, dietary nitrate supplementation with beetroot
juice (BR) reduced the O2 cost of submaximal walking
and running exercise tolerance in young healthy malesThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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club level cyclists [6]. A systematic review and meta-
analysis of the effect of nitrate supplementation on
exercise performance in healthy individuals has demon-
strated that there is a significant moderate beneficial ef-
fect upon exercise performance as measured by time to
exhaustion (effect size = 0.79 (95% CI, 0.23-1.35)).
These benefits were more often observed in inactive to
recreationally active individuals, and are present in both
acute supplementation as well as chronic supplementa-
tion at up to at least 15 days [7].
Dietary nitrate supplementation appears to exert its
effect via augmentation of the oxygen-independent
entero-salivary pathway in which dietary NO3
− is reduced
to biologically active nitrite (NO2
−) and nitrous oxide
(NO), resulting in greater NO availability [8]. This path-
way is conceptualized as a ‘back-up’ to the oxygen-
dependent classical L-arginine NO synthetase system, and
is upregulated under acidemic or anaerobic conditions,
situations conceivably more commonplace in individuals
with COPD [9]. Resultant increased bioavailable NO may
lead to enhanced vasodilation and/or O2 distribution
within skeletal muscle, possibly by increasing the driving
pressure of O2 in the microcirculation [10]. Other pro-
posed mechanisms include increased muscle contractile
efficiency and increased mitochondrial efficiency [11].
It has also been established that nitrate supplementation
also lowers blood pressure, due to a vasodilatory effect
[12,13]. This has safety implications for individuals with
COPD who are often older, more frail and osteopenic and
in whom a fracture may lead to life threatening complica-
tions [14]. The physiology of individuals with COPD greatly
differs to healthy individuals, with a chronic inflammatory
state resulting in disruption to pulmonary tissues, gas ex-
change abnormalities, cardiac dysfunction and skeletal
muscle deconditioning [15]. Compared to healthy controls,
individuals with COPD appear to have preserved baseline
levels of nitrate and nitrite, but NO dynamics are altered,
with differences in NO synthetase isoforms [16-18].
Three recent reports have reported the effects of acute
and short term dietary nitrate supplementation on exer-
cise endurance in individuals with COPD, with mixed
results [19-21].
We performed a randomized, double blind placebo
control crossover trial in order to test the hypothesis
that short term dietary nitrate supplementation (3 days
of 4.8 mmol twice daily) would exert a beneficial effect
on exercise tolerance as measured by submaximal walk
test endurance in individuals with moderate severity,
stable COPD.
Methods
Institutional ethics review was sought and received from
the Southern Health Human Research Ethics Committee(11335A, approval date 24/1/2012). The trial was regis-
tered with the Australia and New Zealand Clinical Trial
Registry (ACTRN12611001088932, registered 20/10/
2011). All participants gave written informed consent
prior to participation and refrained from antibacterial
products including mouthwash and toothpaste during
the study period. Apart from abstaining from beetroot
products, no dietary restrictions were imposed. Partici-
pants’ medications remained unchanged for the duration
of the trial.
BR was chosen as the source of dietary nitrate for this
study for its ready commercial availability and use in prior
literature. BEET-IT shots (James White Drinks, Ipswich,
UK) were used for this study as the 0.3gm (4.8 mmol)
dose of NO3
− in each 70 mL shot approximates the 0.34-
0.38gm (5.5 mmol-6.2 mmol) NO3
− dose as described by
prior investigators [4,5,22] without the requirement for a
500 mL daily fluid intake. Physically identical nitrate-
deplete placebo shots (PL) were obtained from the manu-
facturer (0.00035-0.0013gm (0.0056-0.020 mmol) NO3
−
dose) (personal communication, Pinho, A., James White




Voluntary participants were recruited at a tertiary metro-
politan Australian medical center either directly from the
outpatient pulmonary function test laboratory or by direct
referral from thoracic physicians. Inclusion criteria were
Global Initiative for Chronic Obstructive Lung Disease
(GOLD) class II stable COPD (‘moderate’ severity: FEV 1/
FVC < 0.7, FEV 1 50-79% predicted) [1], age 45–80 and
physical ability to perform an endurance shuttle walk test.
GOLD II severity was chosen as a group who would be
likely to experience exercise limitation but who would still
be able to perform exercise testing. Exclusion criteria in-
cluded a history of acute exacerbation of COPD in the
preceding month, oral corticosteroid therapy, long term
domiciliary O2 therapy, beta blocker therapy, ischemic
heart disease or congestive cardiac failure and musculo-
skeletal problems limiting exercise.
Baseline measurements
At baseline (visit 1), participants underwent pre- and post-
bronchodilator spirometry and measurement of carbon
monoxide diffusing capacity as per American Thoracic
Society/European Respiratory Society standard guidelines
for pulmonary function testing [23] (Figure 1).
During the same visit, participants undertook an incre-
mental shuttle walk test (ISWT) [24], a commonly used
field walking test designed to simulate a maximal cardio-
pulmonary exercise test in individuals with COPD. This
involved timed, accelerating shuttle walking around
cones 9 m apart, forming a 10 m course. Standardized
Visit 1: Baseline spirometry, 
incremental shuttle walk test
(completed: n=31)
Visit 3: Three day blinded BR/PL 
wash-in prior to visit 3 (endurance 
shuttle walk test) then four day 
washout
(completed: n=19)
Visit 4: Crossover phase: Three day 
blinded BR/PL wash-in prior to visit 4 
(endurance shuttle walk test)
(completed: n=19)
Visit 2: Baseline endurance shuttle 
walk test and safety phase 
(completed: n=23)
1 exclusion due to cardiac arrhythmia
1 exclusion due to frequent syncope
1 withdrawal due to interstate relocation
1 withdrawal due to intercurrent illness
2 withdrawals due to intercurrent illness
1 exclusion due to symptomatic postural 
hypotension in safety phase
Recruitment: Consent and medical 
screening (n=35)
4 excluded because they completed the 
baseline incremental shuttle walk test
3 withdrawals due to intercurrent illness
1 strongly disliked taste of BR juice
Screening: Eligible individuals 
identified from spirometry and direct
referrals (n=131)
96 declined participation or met exclusion 
criteria e.g. concurrent beta-blocker usage
Figure 1 Study design. Visits 1 and 2 occurred approximately 1 week apart and collected baseline and safety data on participants. Visits 3 and 4
were exactly 7 days apart per study protocol. Prior to visit 3, participants consumed either beetroot (BR) or placebo (PL) twice a day for three
days. They underwent an endurance shuttle walk test during visit 3 and then abstained from BR for 4 days to allow washout. In the crossover
phase, participants were given to whichever juice (BR or PL) they had not previously been exposed to. This was taken twice a day for three days
prior to visit 4, at which time another endurance shuttle walk test was performed.
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protocol: these included uniform instructions and coach-
ing and a repeat test to account for a learning effect.
The best distance was recorded and used to estimate
V̇O2max and to calculate the walking speed representing
85% of maximal exercise performance for use in the en-
durance shuttle walk test (ESWT) [25].
The ESWT [26] is a constant paced standardized test
of endurance capacity developed for use in patients with
COPD. It has face and construct validity as the exercise
testing regime suitable validated for use in patients with
COPD as a measure reflective of the workload under-
taken by an individual with COPD in the course of their
daily activities. Participants performed the walk under
controlled conditions by walking at a constant predeter-
mined rate around cones 9 m apart (10 m shuttle walk)
to a constant, timed audio recording until exhaustion.The ESWT permits measurement of walking time and
distance at the speed that represents their estimated 85%
V̇O2max; hence it is a measure of the individual’s sub-
maximal exercise endurance capacity.
Previous studies have demonstrated that it is not ne-
cessary to perform repeat determination of either the
ISWT or the ESWT in this patient group [27].
Initial ESWT and safety phase
During visit 2, which occurred approximately a week
after visit 1, an initial ESWT was undertaken. Immedi-
ately after the ESWT, a Modified Borg Rating Scale for
Perceived Dyspnea was recorded [28]. Following this, a
safety phase was performed during which participants
consumed, un-blinded, active BR and underwent meas-
urement of sitting and standing blood pressure, heart
rate and pulse oximetry saturations at 0, 0.5, 1 and
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been previously demonstrated to decrease resting sys-
tolic blood pressure [5]. As pre-specified, if participants
became symptomatic or had a >20 mmHg systolic blood
pressure fall in response to the test dose, they were ex-
cluded from the remainder of the study protocol.
Double blinded randomized placebo controlled phase
Participants were randomized to receive either (active)
BR or PL first in a double blind fashion by computerized
allocation performed by an independent clinical trials
pharmacist.
For three days prior to visit 3, participants consumed
their allocated dose of juice (70 mL) twice per day. They
consumed a final dose of juice on the morning of visit 3,
approximately an hour prior to the performance of the
ESWT. Per protocol, visits 3 and 4 occurred strictly
7 days apart.
Following visit 3, participants abstained from juice
supplementation for four days, allowing a ‘wash-out’
period between dosing regimes. They then consumed
whichever of BR or PL they had not previously been ex-
posed to. This was again taken twice a day for three days
prior to visit 4, with a final supplement on the morning
of visit 4. Visit 4 also consisted of an ESWT.
The timing of supplementation was based on another
randomized double-blind placebo-controlled crossover
study [29], however washout was shortened from 10 to
7 days for logistical reasons.
Trial supplement adherence was checked by self-report
and bottle count.
Sample size estimation
A recent meta-analysis of the effect of nitrate supplemen-
tation on exercise performance in healthy individuals has
demonstrated that there is a significant moderate benefi-
cial effect upon exercise performance as measured by time
to exhaustion with an effect size of 0.79 (95% CI, 0.23-
1.35) [7]. Eaton et al. (2006) reported that the baseline per-
formance by moderate severity COPD patients on the
ESWT was 313 meters, with a standard deviation of 193
meters, and the reported improvement in performance in
response to exercise rehabilitation of 92% of baseline (302
meters). However, using the reported 92% improvement
in ESWT performance in response to pulmonary rehabili-
tation as the minimum clinically important difference
(MCID) results in an effect size of 1.6, leading to a sample
size requirement of only 6–7 patients in a cross-over study
in order for the study to have an 80% power at the 5% sig-
nificance level. A more conservative estimate of the MCID
was used instead. We chose 55% improvement on the
baseline performance in the ESWT as the MCID resulting
in a more conservative estimate of the required sample
size: 20 patients [30].Outcomes and statistical analysis
The pre-specified primary endpoints were distance walked
(meters) and time to fatigue (minutes) on the ESWT on
BR versus that on PL, with comparison by two-sided
paired repeated sample t-tests. Secondary endpoints in-
cluded safety phase data, Borg dyspnea scores and blood
pressure. Analysis was performed using SPSS Statistics for
Windows, Version 20.0 (Armonk, NY, IBM Corp, 2011).
Results are presented as mean ± standard deviation, and
statistical significance accepted if alpha <0.05.
Results
Recruitment
Between March 2012 and October 2013, 131 eligible
participants were identified, 35 of whom agreed to par-
ticipate in the study, 23 of whom completed the safety
phase, and 19 went on to complete all four visits (Table 1
and Figure 1). One patient was excluded at enrolment as
he was detected to have asymptomatic sick sinus syn-
drome. The most common reason for attrition during
the study period was intercurrent illness, predominantly
acute exacerbations of COPD.
Four participants were assessed to be too fit for the
trial following the initial ISWT. On the basis of complet-
ing the ISWT, these excluded participants’ predicted
85% V̇O2max exceeded the measurement ceiling of the
ESWT (approximately 15 ml/min/kg). Any potential in-
crease in walk distance therefore could not be measured
with the ESWT. Therefore these four subjects were ex-
cluded. In the design phase, it was not foreseen that in-
dividuals with moderate COPD would be able to
complete the ISWT.
Baseline data
Of the 19 participants who completed the trial, the mean
age was 67 and 14 were female. Their mean FEV1 was
62.0 ± 6.9% predicted, with TLCO of 53.9 ± 13.9% pre-
dicted. The mean estimated V̇O2max was 14.9 ± 3.8 ml/
min/kg, with a calculated predicted 85% V̇O2max of
12.6 ± 3.2 ml/min/kg.
Numbers analyzed and outcomes
The safety phase (n = 23) confirmed the known blood
pressure effects of BR supplementation. Compared to
sitting blood pressure at the start of the safety phase,
there was a maximal mean systolic blood pressure decre-
ment of 10 mmHg on standing at 1 hour (7.3%) (p =
0.001), accompanied by significant compensatory in-
creases in heart rate at 0 hours (mean increase 6.2 ± 8.0
beats per minute, p = 0.001) and 0.5 hours (3.8 ± 7.5
beats per minute, p = 0.027) (Tables 2 and 3). One par-
ticipant developed symptomatic postural hypotension at
4 hours (30 mmHg drop on sitting to standing at
4 hours) and was excluded from the trial. Diastolic blood
Table 1 Characteristics of participants who completed all
four visits
N (completers) 19
Sex Female: 14 Male: 5
Age (years) 67 ± 7.9
Height (cm) 161.5 ± 8.1
Weight (kg) 76.5 ± 19.1
BMI 29.1 ± 6.5
FEV1 (% predicted) 62.0 ± 6.9
FVC (% predicted) 91.6 ± 12.9
FEV1/FVC 66.0 ± 7.6
TLCO (% predicted) 53.9 ± 13.9
V̇O2max (ml/min/kg) 14.9 ± 3.8
Abbreviations: FEV1: forced expiratory volume in 1 second, FVC: forced vital
capacity, TLCO: transfer factor for carbon monoxide, V̇O2max: maximum
oxygen uptake.
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tion period (Additional file 1: Table S1).
19 participants completed the crossover paired sample
phase of the trial (visits 3 and 4). Adherence to trial sup-
plementation was excellent based on self report and bottle
count, with the majority of participants reporting full
compliance (n = 18) on both occasions and the remaining
subject reporting only one missed dose during the three
day wash-in period.
Participants walked a mean distance of 721.6 ± 587.5 m
on PL and 800.0 ± 584.3 m on BR (difference: 79 m, 11%)
(Table 4). The median for PL was 520 m (interquartile
range 360-795 m), and for BR, the median was 560 m
(interquartile range 420-925 m) (Figure 2). These changes
were not significant (p = 0.494, 95% CI −314.3 to
175.5 m). Similarly, walking time was not changed be-
tween PL (9.9 ± 7.5 minutes) and BR (10.5 ± 6.0 minutes)
(difference = 0.6 minutes, 6%, p = 0.693). After walking,
there was no difference in dyspnea score (Borg scale) or
systolic blood pressure between the PL and BR treatment
arms. These results did not change after removal of out-
liers (analysis not shown).Table 2 Safety phase data for systolic blood pressure on stan
Systolic blood pressure Mean difference from 0 ho
0 hours sitting 136.6 ± 17.6 n/a
0 hours standing 130.9 ± 16.7 −5.7 ± 9.5
0.5 hours standing 129.4 ± 13.4 −8.5 ± 14.7
1 hours standingo 127.6 ± 15.6 −10.0 ± 12.8
4 hours standing 129.0 ± 18.5 −7.5 ± 15.5
*95% confidence interval; +paired sample two tailed t-test; ^significant comparison
to missing data.Discussion
The results of this study indicate that dietary nitrate sup-
plementation in individuals with moderate COPD a) does
not significantly increase submaximal exercise endurance
as measured by ESWT distance, time or dyspnea score
and b) decreases resting systolic blood pressure with c)
compensatory increases in resting heart rate.
Limitations
Unfortunately given logistical (funding) constraints, it was
impractical to measure serum NO3− and NO2− levels:
ideally, these would have been measured at baseline and
post supplementation, with additional analyses carried out
to determine whether improvements in exercise endur-
ance were associated with increased NO3− and/or NO2−,
and whether medications or comorbidities interacted with
this effect. We observed a decrement in blood pressure in
the active arm, suggestive of successful nitrate supplemen-
tation, however, quantitative determination of NO3− and/
or NO2− may have provided definite confirmation. Con-
firmation of return of NO3− and NO2− to baseline values
after the four day washout period may also have been
useful.
Our trial also suffered from a high attrition rate: from
35 subjects, only 19 completed the trial. This is signifi-
cantly higher than in other trials of dietary nitrate sup-
plementation in individuals with COPD, in which
withdrawals were limited to a maximum of 1 per trial
[19-21]. The attrition rate in our study is reflective of
the burden of illness in individuals with COPD, with
multiple drop-outs due to underlying illness or intercur-
rent illness. 10 of our patients withdrew due to medical
illness (predominantly COPD exacerbations), and in the
safety phase, one withdrew with symptomatic postural
hypotension induced by BR, confirming the reported
[5,12] effect of dietary nitrates on blood pressure. These
withdrawals may reflect the tertiary nature of our center,
with a high proportion of more unwell patients.
Comparisons
The dose and timing of nitrate used in our study differed
to that used by other investigators who have examinedding (mmHg) (n = 23 unless otherwise stated)
urs sitting SBP Compared to 0 hours sitting SBP 95% CI* P value+
n/a n/a
−1.6 to −9.8 0.009^
−2.0 to −15.0 0.012^
−4.5 to −16.0 0.001^
−0.8 to −14.3 0.029^
at the 95% confidence level; on = 22 for the 1 hour standing comparison due
Table 3 Safety phase data for heart rate (HR) on standing (beats per minute) (n = 23 unless otherwise stated)
Heart rate Mean difference from 0 hours
sitting HR
Compared to 0 hours
sitting HR 95% CI*
P value+
0 hours sitting 88.2 ± 11.9 n/a n/a n/a
0 hours standingo 94.3 ± 13.0 6.2 ± 8.0 2.8 to 9.7 0.001^
0.5 hours standing 92.4 ± 9.9 3.8 ± 7.5 0.47 to 7.1 0.027^
1 hours standing 92.0 ± 11.9 3.9 ± 10.0 −0.43 to 8.2 0.076
4 hours standing 87.7 ± 11.4 −0.478 ± 13.4 −6.3 to 5.3 0.866
*95% confidence interval; ^significant comparison at the 95% confidence level; +paired sample two tailed t-test; on = 22 for the 0 hour standing comparison due
to missing data.
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and Berry et al., both of whom found positive effects,
used acute doses of 12.9 mmol and 7.58 mmol respect-
ively [19,20]. However, Shepherd et al. used 6.77 mmol
twice a day for 2.5 days and found no difference [21].
We used 4.8 mmol twice a day for three days with a fur-
ther dose on the morning of walk test and found no sig-
nificant difference. Although a trial in healthy cyclists
used a wash-in period and demonstrated benefit (three
days 0.1 mmol nitrate/kg/day) [29], it is possible that
physiological alterations in aging, or in COPD render
wash-in periods less useful, or alternatively, that the dose
we used was too low.
The effect of increased adiposity has been proposed as
a modifying factor in the response to dietary nitrate, by
means that are unknown [21]. The BMI (kg/m2) of our
study population (29.1 ± 6.5) was similar to that in Berry
et al. (29.2 ± 5.5) who found similar an increase in exer-
cise performance. Kerley et al. had a slightly lighter
population and found an increase in exercise endurance
with a BMI of 27.3 ± 6.4, whereas Shepherd et al., whose
patients were heavier than ours, and found no difference
with a BMI of 30.8 ± 3.2. The influence of adiposity on
nitrate supplementation’s effect on exercise supplemen-
tation remains yet to be defined.
In healthy older individuals, short term dietary nitrate
supplementation at 9.6 mmol/day reduced resting blood
pressure but there was no effect on walk time, an effect
broadly similar to our findings [31]. Interestingly, al-
though decreases in the oxygen cost of submaximal ex-
ercise have been relatively consistently found in youngerTable 4 Study outcomes for pre-specified primary and second
PL phase mean
ESWT walking distance (m) 721.6 ± 587.5
ESWT walking time (min) 9.9 ± 7.5
Borg scale 3.41 ± 2.0
Systolic blood pressure prior to ESWT (mmHg) 132 ± 16.2
Systolic blood pressure after ESWT (mmHg) 159.8 ± 26.6
*95% confidence interval; +paired sample two tailed t-test.individuals [7], the oxygen cost of submaximal exercise
was not decreased in those healthy older individuals, for
reasons that are unclear. Additionally, decreases in the
oxygen cost of exercise were not found in the studies of
nitrate supplementation of individuals with COPD, sug-
gesting that if exercise endurance is increased in COPD,
the mechanisms may be different to that in younger in-
dividuals [20,21].
We found a heterogeneous response to dietary nitrate
in our study population, consistent with Berry et al. who,
despite an overall positive effect, found that two of their
11 participants had a decrease in exercise time. This
variation in response was also noted by Kerley et al., and
its mechanism remains unclear. It may therefore be that
individuals with COPD differ in their response to dietary
nitrate and that our study population may have been
comprised of a greater proportion of non-responders.
Skeletal muscle in individuals with COPD may affected
by myriad factors, which include deconditioning, hyp-
oxia, hypercapnia, systemic inflammation, malnutrition,
and drug therapy. Multiple abnormalities result, includ-
ing redox imbalance, autophagy induction, mitochon-
drial dysfunction, a protein catabolic state with reduced
anabolism and structural abnormalities [32]. Intriguingly,
it also appears that epigenetic modification may play a
role in muscle phenotype and performance in COPD
[33]. Additionally, exercise limitation may result from
not only skeletal muscle factors, but also lung and
haemodynamic factors [34]. These complex, interwoven
factors and their varying extents in any given individual
with COPD may make prediction of response to dietaryary endpoints
BR phase mean 95% CI* P value+
800.0 ± 584.3 −314.3 to 157.5 0.494
10.5 ± 6.0 −3.4 to 2.3 0.693
3.1 ± 1.6 −0.2 to 0.9 0.244
134.6 ± 18.2 −12.9 to 7.8 0.962


















ESWT on PL ESWT on BR
Figure 2 ESWT distance change. Figure 2a: Plot of individual participants’ endurance shuttle walk test (ESWT) distances (n = 19). Figure 2b: Box
and stem plots of individual participants’ endurance shuttle walk test (ESWT) (n = 19). Abbreviations: BR: beetroot juice, PL: placebo.
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render it challenging to precisely identify a mechanism
for exercise enhancement, if it exists.Study design
An important question arising from this study is whether
the observed difference in endurance distance (11%) and
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distance of 60-115 m has been reported as a minimally
clinically important difference in the ESWT in the context
of a pharmacological trial [35]. In our study, the observed
incremental improvement in ESWT was only 79 m whilst
the standard deviation of the observed values for in the
baseline ESWT was 583 m. These values represent a
much reduced effect size of approximately 14% compared
with our initial estimate of 55%. Were the sample size
larger and the standard deviation reduced, the change
in distance may have been clinically significant. An im-
portant question is therefore whether the study was
under-powered.
Study sample size estimates prior to this study were
based on estimates of effect sizes derived from the pub-
lished evidence. A meta-analysis of the effect of nitrate
supplementation on exercise performance in healthy in-
dividuals has demonstrated that there is a significant
moderate beneficial effect upon exercise performance as
measured by time to exhaustion (effect size = 0.79 (95%
CI, 0.23-1.35) [7]). Estimates of the effect size derived
from studies of the incremental effect of pulmonary re-
habilitation program upon exercise distance and time in
the endurance shuttle walk test ESWT yielded an effect
size of 1.6 [36]. This was deemed to be a clinically im-
portant incremental improvement, and was therefore
used as a guide for the choice of effect size for the power
calculation for this study. We used the published ESWT
data to inform us of the anticipated incremental im-
provement and the standard deviation for baseline
performance.
The sample size we chose reflected favorably with the
sample sizes chosen for recently reported studies of diet-
ary nitrate supplementation in COPD, in which sample
size ranged from 11–15 [19-21]. Our trial, with a final
sample size of 19, did not demonstrate an effect of diet-
ary nitrate supplementation in COPD, concordant with
the results of Shepard et al. (n = 13) [21]. This contrasts
with the results of Berry et al. and Kerley et al., who
found a positive effect on exercise performance for diet-
ary nitrate supplementation in COPD, and whose sample
sizes were 15 and 11 respectively [20,31].
Conclusion
Our results do not support a role for the routine use of
acute dietary nitrate supplementation in individuals with
GOLD stage II COPD for the purposes of physical activ-
ity limitation. Whilst this trial, to our knowledge, is the
largest trial of nitrate supplementation in individuals
with COPD, other investigators have reported positive
effects on exercise endurance for dietary nitrate supple-
mentation in COPD. A consistent finding is decreased
blood pressure, and with the development of symptom-
atic postural hypotension seen in one individual in ourstudy, the role and risk-benefit ratio of acute dietary ni-
trate supplementation remains undefined. Overall, it is
difficult draw a firm conclusion as to whether acute diet-
ary supplementation for exercise endurance in COPD is
effective given study heterogeneity (nitrate dose and
form, study setting, exercise methodology).
Future directions
Given the discordance between this study and other re-
cently published literature, further studies should recruit
larger patient cohorts, in order to minimize the effect of
type II error and to examine an interaction between ni-
trate, medications and comorbidities. The identification
of a dose–response relationship for both exercise endur-
ance and hypotension would be important if an effect
for the former were to be confirmed and nitrate were to
be extended to routine clinical use. Further pharmaco-
dynamics studies could also establish whether tolerance
develops. An important step would be to identify whether
there are distinct phenotypes or subpopulations of COPD
that can be classified into nitrate responders or non-
responders, and in whom hypotension may be an issue.
An important study to perform in the future may be to
examine for a potential interaction in effects on submaxi-
mal exercise endurance between a pulmonary rehabilita-
tion program and dietary nitrate supplementation. Such a
study will likely need to be a multicenter randomized
double blind placebo controlled study enrolling large
numbers of subjects to be recruited given the likely drop
out rate may approach 50%. The results of this study may
help inform sample size estimates for such a study.
Additional file
Additional file 1: Table S1. Safety phase data for diastolic blood
pressure (DBP) on standing (mmHg) (n=23 unless otherwise stated).
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